News

Viking Therapeutics (NASDAQ: VKTX) is at an exciting point in its history. While it doesn't have any medicines approved for sale at the moment, it has a couple of mid-stage programs that are shaping

The S&P 500 remains near record levels as the markets have been strong this year. Finding good stocks to buy in such a hot market can be challenging. But a couple of growth stocks with lots of

A business can look to be in solid shape but still not necessarily be a great investment overall. A good example of that is Viking Therapeutics (NASDAQ: VKTX). The company has been doing a lot of

Novavax (NASDAQ: NVAX) stock is suddenly a buy again this year, with its stock price more than tripling since the start of 2024. Some positive developments in recent months, including a deal with

Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 6.8% lower as of 11:19 a.m. ET on Tuesday. The decline came after Culper Research announced a short position in the biotech stock before the

Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver

The biotech industry features many prominent companies that command plenty of attention on the market. And since the year started, few biotechs have made more noise than Viking Therapeutics (NASDAQ:

Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer

On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words

Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades.

On June 6, the U.S. Food

Oil prices dropped like a rock this week and that hit oil-related stocks hard. Ironically, it was OPEC+ extending production cuts that sent oil lower, which seems a little backward.

According to

Cathie Wood doesn't take any trading days off. The co-founder and CEO of Ark Invest publishes her transactions for the family of exchange-traded funds she manages. She didn't make a lot of moves on

Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on

Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to

According to data provided by S&P Global Market Intelligence, shares of DraftKings (NASDAQ: DKNG) dropped by as much as 15.7% in trading this week after the Illinois Senate approved a new budget

May has been an adventurous month for Viking (NYSE: VIK). The world's leading operator of river cruise sailings went public at $24 on May 1. On Wednesday, it delivered its first financial update as

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade around $62. At Friday's prices, a paltry $100 investment in 2022 would

If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (NASDAQ: VKTX). Although the

The inviting market waters greeted a new cruise line operator earlier this month. Viking (NYSE: VIK) completed its initial public offering (IPO) on May 1, pricing a little more than 64 million

Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown

The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful

Up 260% so far this year, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity thanks to its increasingly promising therapies in development to treat obesity. But as wise investors know

Novavax (NASDAQ: NVAX) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock

Vaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax